ETRIPAMIL

Etripamil is a fast‑acting intranasal calcium‑channel blocker designed to terminate paroxysmal supraventricular tachycardia by reducing AV‑nodal conduction. Benefits include rapid self‑administration during episodes. Side effects include nasal irritation, dizziness, hypotension, and mild ECG changes.

Product Description


Mechanism of Action

ETRIPAMIL (ID 33235) exhibits a high-dimensional biochemical activity profile integrating catalytic‑domain modulation, multi‑axis signalling disruption, mitochondrial‑network recalibration, ion‑flux redistribution, redox‑state restructuring, cytoskeletal remodelling, membrane‑electrochemical modulation and transcription‑factor pathway reprogramming. Its molecular architecture supports high‑affinity interaction with catalytic residues, allosteric regulators, hydrophobic receptor pockets, transmembrane helices, nucleotide‑binding pockets, redox‑buffer matrices and polymeric scaffolding complexes—granting broad mechanistic influence across metabolic, genomic, electrophysiological and structural systems.

ETRIPAMIL may reorganise phosphorylation‑flow geometry across ERK/MAPK/JNK/p38 cascades, alter PI3K–AKT survival signalling, shift G‑protein coupling patterns, redistribute Ca²⁺ microdomains, reshape IP₃/DAG signalling topology, and recalibrate cAMP–PKA amplitude dynamics. Mitochondrial impacts include ETC‑complex activation shifts, ATP/ADP turnover modulation, ROS‑threshold displacement, mitochondrial‑membrane potential polarity changes and ER–mitochondrial stress‑signal coupling, making the compound highly valuable for mechanistic and translational research models.

Advanced Research Applications

  • Kinome‑scale catalytic‑cascade mapping and interference modelling
  • Ultra‑resolution ligand docking and conformational‑transition analysis
  • UPR/ER‑stress, mitophagy, autophagy and oxidative‑stress cross‑network characterisation
  • Multi‑omics system reconstruction (RNA‑seq, metabolomics, proteomics, phosphoproteomics)
  • Cytoskeletal mechanics and polymer‑turnover modelling
  • Cell‑fate mapping across apoptosis, necroptosis, ferroptosis, pyroptosis and parthanatos
  • Machine‑learning driven SAR/QSAR molecular‑performance prediction

Toxicodynamics & Cellular Hazard Spectrum

  • ROS hyper‑accumulation and antioxidant‑system collapse
  • Mitochondrial fragmentation, ETC shutdown or hyper‑leak states
  • Severe Na⁺/K⁺/Ca²⁺ ionic‑flux dysregulation
  • Cytoskeletal depolymerisation and membrane‑integrity failure
  • NF‑κB, STAT and IRF inflammatory‑axis hyperactivation
  • Engagement of multi‑axis programmed‑cell‑death pathways
  • Epigenetic drift including methylation and acetylation imbalance

For expert laboratory research only — not intended for biological or therapeutic exposure.

Datasheet


Molecular Formula

C27H36N2O4

Molecular Weight

452.6 g/mol

CAS Number

1593673-23-4

Storage Condition

Store in a cool, dry place. Keep container tightly closed. Protect from moisture and light.

Solubility

Solubility depends on solvent and conditions (e.g., pH). Please contact us for solvent-specific guidance.

Purity

Purity information is available upon request (COA).

Synonym

Etripamil; 1593673-23-4; MSP-2017; (-)-MSP-2017; Etripamilo

IUPAC/Chemical Name

methyl 3-[2-[[(4S)-4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-methylamino]ethyl]benzoate

InChl Key

VAZNEHLGJGSQEL-MHZLTWQESA-N

InChl Code

InChI=1S/C27H36N2O4/c1-20(2)27(19-28,23-11-12-24(31-4)25(18-23)32-5)14-8-15-29(3)16-13-21-9-7-10-22(17-21)26(30)33-6/h7,9-12,17-18,20H,8,13-16H2,1-6H3/t27-/m0/s1

References

https://pubchem.ncbi.nlm.nih.gov/compound/91824132;

3D Conformer.

(Click, turn or enlarge)

Download our GMP API Product List.

MedicaPharma is an EU-based supplier of GMP-certified APIs that serves leading healthcare institutions and research organizations.
Click here to download our full API product list.

Download